Stockpolly
Search
VCRE · NASDAQ · Biotechnology

Vicore Pharma (VCRE)

Develops oral AT2 receptor agonists for idiopathic pulmonary fibrosis.

$11.26
At close+0.19 (+1.71%)
Watchlist

In millions of USD, except per-share figures · converted from SEK at the latest rate

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue01000000000
Cost of revenue50000000000
Gross profit−51000000000
716611012114132
Research & development57551810112111
21110110220
Selling & marketing00000000000
General & administrative21110110220
Other expenses0−7000000000
Operating income−32−18−19−19−1−10−12−1−14−13−2
12220−200020
Interest income00000110120
Interest expense00000320100
Other non-operating income00000−1−10−1−20
Income before tax−31−16−17−17−1−12−12−1−14−11−2
Income tax expense00000000000
Net income from continuing operations−123−1−6−1−12−12−1−14−11−2
Net income580−1−6−1−12−12−1−14−11−2
EPS, basic−$0.01$0.00−$0.00−$0.01−$0.00−$0.50−$0.51−$0.01−$0.56−$0.41−$0.01
EPS, diluted−$0.01$0.00−$0.00−$0.01−$0.00−$0.50−$0.51−$0.01−$0.56−$0.41−$0.01
Weighted average shares, basic11211211211221623232352628280
Weighted average shares, diluted11211211211221623232352628280
EBITDA−30−15−1−1−1−9−11−1−13−110
Depreciation & amortization00000000002
EBIT−31−16−7−1−1−9−11−1−13−11−2